Abstract:Trichosanthin (TCS), as a type 1 ribosome-inactivating protein, has a very high cytoplasmic activity in vitro and can quickly kill cancer cells. However, it is easily filtered and cleared by the kidney, which results in the short half-life and severely limits its application. In this study, we constructed several recombinant proteins by fusing the albumin binding domain mutant ABD035(abbreviated as ABD) to the N-or C-terminus of TCS to endow the recombinant TCS fusion protein with a longer half-life property binding with endogenous human serum albumin (HSA) via ABD to effectively exert its anti-tumor activity in vivo. Pull down, Dynamic light scattering and ELISA assays all showed that TCS fused with two ABD sequences at the C-terminus of TCS, has stronger binding capacity to HSA in vitro than TCS with one ABD. In vivo studies in BALB/C mice were performed and the elimination half-life of TCS-ABD-ABD is about 15-fold longer compared to TCS and anti-tumor activity is about 30% higher than that of TCS alone in BALB/C mouse experiments. Moreover, we found that TCS with two ABDs in tandem have the highest soluble expression level, more than 5 times higher than that of TCS, and the yield of purified protein of TCS-ABD-ABD was as high as 68.9 mg/L culture solution, which was about 7-fold higher than that of TCS. Furthermore, MTT assay showed that the anti-tumor activity of TCS-ABD-ABD was significantly higher than TCS fused with only one ABD sequence, indicating that the repeated ABD sequences facilitated the biological activity of TCS. In this paper, the fusion of the albumin-binding domain in tandem with TCS can effectively improve its stability in vivo and also significantly increase its soluble expression, expanding the application of the albumin -binding domain in the high soluble expression and stability of protein drugs.

[A comparative study on the properties of trichosanthin before and after site-directed PEGylation].

Primary studies on the properties of trichosanthin after site-directed mutagenesis and PEGylation

Effect of Site-Directed PEGylation of Trichosanthin on Its Biological Activity, Immunogenicity, and Pharmacokinetics

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation

Site-directed Polyethylene Glycol Modification of Trichosanthin: Effects on Its Biological Activities, Pharmacokinetics, and Antigenicity.

Site-directed Polyethylene Glycol Modification of Trichosanthin

Site-directed Mutation of Trichosanthin and Chemical Modification of Mutant by Polyethylene Glycol

Mapping the Antigenic Determinants and Reducing the Immunogenicity of Trichosanthin by Site-Directed Mutagenesis

Effect of Structural Modification of Trichosanthin on Its Abortifacient Activity

Y55 and D78 Are Crucial Amino Acid Residues of a New IgE Epitope on Trichosanthin

High--level Expression of Recombinant Trichosanthin in {\sl Escherichia Coli} and Evaluation of Its Immunogenicity

Site-Directed Mutagenesis and Prokaryotic Expression of Trichosanthin

Synthesis, Characterization and Cytotoxicity of Poly(ethylene Glycol)-Graft-trimethyl Chitosan Block Copolymers.

Effects of quaternization and PEGylation on the biocompatibility, enzymatic degradability and antioxidant activity of chitosan derivatives

HIGH-LEVEL EXPRESSION OF RECOMBINANT TRICHOSANTHIN IN ESCHERICHIA COLI AND EVALUATION OF ITS IMMUNOGENICITY

Tandem Fusion of Albumin-Binding Domains Promoted Soluble Expression and Stability of Recombinant Trichosanthin in Vitro and in Vivo.

Synthesis and characterization of PEG modified N-trimethylaminoethylmethacrylate chitosan nanoparticles

Study on the bioactivity and immunogenicity of TCSKR173-174CG,a trichosanthin mutant

N-terminal Site-Specific PEGylation Enhances the Circulation Half-Life of Thymosin Alpha 1

Studies on the Pegylation of Protein at A Specific Site: Sulfhydryl-Pegylation of 97Cys-Ifn-gamma

Site-specific PEGylation Strategies and Suitable Modified Sites of Protein Drugs